PMID- 16019503
OWN - NLM
STAT- MEDLINE
DCOM- 20050915
LR  - 20190116
IS  - 1042-8194 (Print)
IS  - 1026-8022 (Linking)
VI  - 46
IP  - 5
DP  - 2005 May
TI  - Dendritic cells from patients with chronic myeloid leukemia: functional and 
      phenotypic features.
PG  - 663-70
AB  - Dendritic cells (DCs) are professional antigen-presenting cells playing a pivotal 
      role in the induction of humoral and cellular immune responses, and chronic 
      myeloid leukemia-derived DCs (CML-DCs) are possible candidates for inducing 
      anti-leukemic immunity. This review describes phenotypic and functional features 
      of DCs derived from CML patients as compared with DCs from healthy volunteers. In 
      short, distinct deficiencies have been reported for CML-DCs, such as reduced 
      migration, endocytosis, phagocytosis, antigen processing, DC maturation and 
      cytokine production. DC abnormalities of CML patients can be abrogated by proper 
      in vitro stimulation of leukemic DCs. This underscores the importance of proper 
      generation and maturation of CML-DCs when considering clinical vaccination 
      protocols.
FAU - Eisendle, Klaus
AU  - Eisendle K
AD  - Laboratory for Tumor and Immunobiology, Division of Hematology and Oncology, 
      Innsbruck Medical University, Innsbruck, Austria. klaus.eisendle@uibk.ac.at
FAU - Wolf, Dominik
AU  - Wolf D
FAU - Gastl, Guenther
AU  - Gastl G
FAU - Kircher-Eibl, Brigitte
AU  - Kircher-Eibl B
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Benzamides)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Cytokines)
RN  - 0 (Piperazines)
RN  - 0 (Pyrimidines)
RN  - 8A1O1M485B (Imatinib Mesylate)
RN  - EC 2.7.10.2 (Fusion Proteins, bcr-abl)
SB  - IM
MH  - Antineoplastic Agents/therapeutic use
MH  - Benzamides
MH  - Cancer Vaccines/therapeutic use
MH  - Cytokines/biosynthesis
MH  - Dendritic Cells/drug effects/*immunology
MH  - Fusion Proteins, bcr-abl/immunology
MH  - Humans
MH  - Imatinib Mesylate
MH  - Immunophenotyping
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*immunology/therapy
MH  - Lymphocyte Activation
MH  - Myeloid Cells/immunology
MH  - Piperazines/therapeutic use
MH  - Pyrimidines/therapeutic use
MH  - T-Lymphocytes/immunology
RF  - 67
EDAT- 2005/07/16 09:00
MHDA- 2005/09/16 09:00
CRDT- 2005/07/16 09:00
PHST- 2005/07/16 09:00 [pubmed]
PHST- 2005/09/16 09:00 [medline]
PHST- 2005/07/16 09:00 [entrez]
AID - VJ15X21312187211 [pii]
AID - 10.1080/10428190400029825 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2005 May;46(5):663-70. doi: 10.1080/10428190400029825.